| |
| |
|
| Insider
Information: |
Tessier-Lavigne Marc |
| Relationship: |
Director |
| City: |
So San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,228,119 |
|
|
Indirect Shares
|
236,869 |
|
|
| Direct
Value |
$41,592,854 |
|
|
|
Indirect Value
|
$4,550,253 |
|
|
| Total
Shares |
2,464,988 |
|
|
| Total
Value |
$46,143,107 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 42.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pfizer Inc |
PFE |
Director |
2011-12-12 |
104 |
|
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2013-07-24 |
101,009 |
|
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2014-12-23 |
250,000 |
|
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
1,874,572 |
2023-06-01 |
236,869 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2020-05-06 |
4 |
OE |
$177.82 |
$2,667,300 |
D/D |
15,000 |
16,830 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
OE |
$380.95 |
$2,833,887 |
D/D |
7,439 |
9,708 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-16 |
4 |
AS |
$675.00 |
$2,943,675 |
D/D |
(4,361) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
OE |
$376.69 |
$2,949,483 |
D/D |
7,830 |
10,099 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2015-08-05 |
4 |
S |
$584.07 |
$2,951,275 |
D/D |
(5,000) |
1,187 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2013-05-06 |
4 |
S |
$260.20 |
$3,478,942 |
D/D |
(13,334) |
0 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-09-13 |
4 |
OE |
$273.67 |
$3,489,293 |
D/D |
12,750 |
14,828 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
AS |
$690.00 |
$5,132,910 |
D/D |
(7,439) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
AS |
$680.00 |
$5,324,400 |
D/D |
(7,830) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2020-02-13 |
4 |
S |
$398.71 |
$5,711,711 |
D/D |
(14,279) |
1,830 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-03-01 |
4 |
AS |
$64.36 |
$6,622,207 |
D/D |
(100,000) |
2,642,296 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-07 |
4 |
AS |
$70.35 |
$6,639,523 |
D/D |
(94,378) |
2,544,370 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-09-13 |
4 |
AS |
$636.64 |
$8,181,827 |
D/D |
(12,750) |
2,078 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2020-05-06 |
4 |
S |
$562.65 |
$8,459,496 |
D/D |
(15,000) |
1,830 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-06-16 |
4 |
S |
$26.10 |
$10,440,000 |
D/D |
(400,000) |
2,739,043 |
0 |
% |
|
65 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
